View Press Releases

Novo Nordisk has taken legal action against Eli Lilly, escalating the competition between two of the world’s leading pharmaceutical companies in the rapidly expanding GLP-1 obesity and diabetes treatment market. On July 21, 2026, Novo Nordisk announced that it filed a lawsuit against Eli Lilly and Lilly USA in the U.S. District Court for the District of New Jersey, alleging that Lilly’s national advertising campaigns for Zepbound® (tirzepatide) and Mounjaro® (tirzepatide) create a misleading impression about treatment superiority. The lawsuit claims that Lilly’s direct-to-consumer advertisements use outdated clinical comparisons while excluding important scientific evidence about newer, higher-dose options available for …

The health and wellness industry continues to expand as consumers become more focused on preventive healthcare and daily nutrition. With this growth comes increased competition, making it essential for brands to deliver high-quality products that meet strict industry standards. Choosing supplement manufacturing services from a trusted partner allows businesses to launch products confidently while ensuring consistency, safety, and customer satisfaction. A reliable manufacturing company not only produces supplements but also supports brands throughout the entire product development journey. From formulation and ingredient sourcing to packaging and quality testing, the right partner helps simplify every stage of production. Comprehensive Manufacturing Solutions …

Phenomix Sciences (Phenomix), the first commercial precision obesity medicine biotechnology company, today announced that patients can now order the MyPhenome® genetic obesity test directly through the company’s website and supported by its physician network.  More than 30 million American adults are taking GLP-1s, but up to 30% see disappointing to little weight loss. For many patients, that can mean months of frustration, significant out-of-pocket costs, and delayed progress before discovering that another treatment approach may have been a better fit. While obesity specialists have a growing number of evidence-based treatments available – including GLP-1 medications, phentermine-topiramate, naltrexone-bupropion, bariatric surgery and …

Restorative Formulations has released the NeuroSynergy Clinical Series, a new line of four professional dietary supplement formulas designed for use in naturopathic and functional medicine practices to support mental wellness. The series was developed by Michaël Friedman, ND, Chief Formulator and Founder of Restorative Formulations. Each formula in the line includes unique ingredients and addresses a specific neurochemical pathway, allowing practitioners to select the most appropriate option based on individual patient presentations. "Mental wellness has become an increasingly common concern today for clinicians treating patients, whether it's mood, stress, or cognitive changes. I developed the NeuroSynergy Clinical Series to give …

Calgary, Alberta, Canada – February 18, 2026 – IGY Immune Technologies & Life Sciences Inc. (“IGY Life Sciences”) is pleased to announce the publication of its latest clinical research in the peer-reviewed journal Nutrients, published by MDPI. The 12-week randomized, double-blind, placebo-controlled pilot trial evaluated the effects of Muno-IgY® supplementation on markers of immune function, respiratory wellness, exercise-related physiological stress, and gut microbiome profiles in healthy adults. Muno-IgY® is a targeted Immunoglobulin Y (IgY) ingredient derived from hen egg yolk and developed to support normal gut and immune function through selective binding interactions within the gastrointestinal tract. Key observations from …

BoomRx, the fastest-growing national pharmaceutical technology platform that simplifies prescription sourcing and fulfillment, today announced the availability of oral semaglutide and tirzepatide options utilizing advanced nanoemulsion delivery for medical clinics, med spas, wellness practices, and telemedicine providers nationwide. The newly introduced formulations apply nanoemulsion technology to convert each dose into microscopic particles, supporting more uniform dispersion and enhanced absorption. This injection-free delivery option offers healthcare providers greater flexibility and consistency as weight-management programs continue to evolve into long-term, scalable care models. “Semaglutide and tirzepatide have become foundational therapies in weight management, and how they’re delivered matters,” said Kurt Lunkwitz, founder …